DaTSCAN
ioflupane (123l)
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for DaTSCAN. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for DaTSCAN.
Authorisation details
Product details | |
---|---|
Name |
DaTSCAN
|
Agency product number |
EMEA/H/C/000266
|
Active substance |
ioflupane (123l)
|
International non-proprietary name (INN) or common name |
ioflupane (123l)
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
V09AB03
|
Publication details | |
---|---|
Marketing-authorisation holder |
GE Healthcare B.V.
|
Revision |
23
|
Date of issue of marketing authorisation valid throughout the European Union |
27/07/2000
|
Contact address |
GE Healthcare B.V. |
Product information
10/05/2021 DaTSCAN - EMEA/H/C/000266 - N/0061
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Diagnostic radiopharmaceuticals
Therapeutic indication
This medicinal product is for diagnostic use only.
DaTSCAN is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:
- In adult patients with clinically uncertain Parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from Parkinsonian syndromes related to idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. DaTSCAN is unable to discriminate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
- In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. DaTSCAN is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia.